CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk

Brain Research

Volumn 1232, Issue , 2008, Pages 1-6

  Qureischie, Homeira ^a   Heun, Reinhard ^b   Lütjohann, Dieter ^a   Popp, Julius ^a   Jessen, Frank ^a   Ledschbor Frahnert, Christine ^a   Thiele, Holger ^c   Maier, Wolfgang ^a   Hentschel, Frank ^d   Kelemen, Peter ^d   Kölsch, Heike ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Alzheimer's disease; APOE4; CETP; Cholesterol

Indexed keywords

CHOLESTEROL; CHOLESTEROL DERIVATIVE; CHOLESTEROL ESTER TRANSFER PROTEIN; LATHOSTEROL;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CHOLESTEROL METABOLISM; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; HYDROXYCHOLESTEROLS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK;

EID: 50849131196     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.07.047     Document Type: Article

References (41)

1. Arias-Vasquez A., Isaacs A., Aulchenko Y.S., Hofman A., Oostra B.A., Breteler M., and van Duijn M. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics 8 (2007) 189-193
2. Barzilai N., Atzmon G., Derby C.A., Bauman J.M., and Lipton R.B. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology 67 (2006) 2170-2175
3. Becker T., and Knapp M. A powerful strategy to account for multiple testing in the context of haplotype analysis. Am. J. Hum. Genet. 75 (2004) 561-570
4. Becker T., and Knapp M. Maximum-likelihood estimation of haplotype frequencies in nuclear families. Genet. Epidemiol. 27 (2004) 21-32
5. Björkhem I., and Meany S. Brain cholesterol: long secret life behind a barrier. Atheroscler. Thromb. Vasc. Biol. 24 (2004) 806-815
6. Borggreve S.E., Hillege H.L., Bruce H., Wolffenbuttel R., De Jong P.E., Bakker S.J.L., van der Steege G., van Tol A., and Dullaart R.P.F. The effect of cholesteryl ester transfer protein -629 C → A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J. Clin. Endocrinol. Metab. 90 (2005) 4198-4204
7. Bretillon L., Siden A., Wahlund L.O., Lütjohann D., Minthon L., Crisby M., Hillert J., Groth C.G., Diczfalusy U., and Bjorkhem I. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci. Lett. 293 (2000) 87-90
8. Bruce C., Sharp D.S., and Tall A.R. Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J. Lipid Res. 39 (1998) 1071-1078
9. Chen D.W., Yang J.F., Tang Z., Dong X.M., Feng X.L., Yu S., and Chan P. Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk of Alzheimer's disease as a modifier for APOE4 in Chinese. Brain Res. 1187 (2008) 52-57
10. Dachet C., Poirier O., Cambien F., Chapman J., and Rouis M. New functional promoter polymorphism, CETP/ -629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels (role of SP1/Sp3 in transcriptional regulation). Aterioscler. Thromb. Vasc. Biol. 20 (2000) 507-515
11. Dupuy A.M., Mas E., Ritchie K., Descomps B., Badiou S., Cristol J.P., and Touchon J. The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer's disease. Gerontology 47 (2001) 213-218
12. Fidani L., Goulas A., Crook R., Petersen R.C., Tangalos E., Kotsis A., and Hardy J. An association study of the cholesteryl ester transfer protein TaqI B polymorphism with late onset Alzheimer's disease. Neurosci. Lett. 357 (2004) 152-154
13. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
14. Frisdal E., Klerkx A.H., Le Goff W., Tanck M.W., Lagarde J.P., Jukema J.W., Kastelein J.J., Chapman M.J., and Guerin M. Functional interaction between -629C/A, -971G/A and -1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP. Hum. Mol. Genet. 14 (2005) 2607-2618
15. Hamilton G., Proitsi P., Jehu L., Morgan A., Williams J., O'Donovan M.C., Owen M.J., Powell J.F., and Lovestone S. Candidate gene association study of insulin signalling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144 (2007) 508-516
16. Heverin M., Bogdanovic N., Lütjohann D., Bayer T., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B., and Björkhem I. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 45 (2004) 186-193
17. Hixson J.E., and Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31 (1990) 545-548
18. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachmann D.A. Statins and the risk of dementia. Lancet. 356 (2000) 1627-1631
19. Kivipelto M., Helkala E.L., Laaksom M.P., Hanninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., and Nissinen A. Midlife vascular risk factors and Alzheimer's Disease in later life: longitudinal, population based study. BMJ 322 (2001) 1447-1451
20. Klerkx A.H., Tanck M.W., Kastelein J.J., Molhuizen H.O., Jukema J.W., Zwinderman A.H., and Kuivenhoven J.A. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629 C → A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum. Mol. Genet. 12 (2003) 111-123
21. Kölsch H., Heun R., Kerksiek A., von Bergmann K., Maier W., and Lütjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 368 (2004) 303-308
22. Lira M.E., Lloyd D.B., Hallowells S., Milos P.M., and Thompson J.F. Highly polymorphic repeat region in the CETP promoter induces unusual DNA structure. Biochim. Biophys. Acta 1684 (2004) 38-45
23. Lütjohann D., Breuer O., Ahlborg G., Nennesmo I., Sidén A., Diczfalusy U., and Björkhem I. Cholesterol homeostasis in human brain: evidence for an age dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. USA 93 (1996) 9799-9804
24. Lütjohann D., Papassotiropoulos A., Björkhem I., Locatelli S., Bagli M., Oehring R.D., Schlegel U., Jessen F., Rao M.L., von Bergmann K., and Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41 (2000) 195-198
25. Mielke M.M., Zandi P.P., Sjogren M., Gustafson D., Ostling S., Steen B., and Skoog J. High total cholesterol levels in late life is associated with a reduced risk of dementia. Neurology 64 (2005) 1689-1695
26. Miettinen T.A., Tilvis R.S., and Kesāniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male Population. Am. J. Epidemiol. 131 (1990) 20-31
27. Montine T.J., Montine K.S., and Swift L.L. Central nervous system lipoproteins in Alzheimer's disease. Am. J. Pathol. 151 (1997) 1571-1575
28. Morozova S., Suc-Royer I., and Auwerx J. Cholesterol metabolism modulators in future drug therapy for atherosclerosis. Med. Sci. (Paris) 21 (2005) 53-58
29. Mulder M., Ravid R., Swaab D.F., de Kloet E.R., Haasdijk E.D., Julk J., van der Boom J.J., and Havekes L.M. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disord. 12 (1998) 198-203
30. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., and Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiol. 17 (1998) 14-20
31. Rodríguez E., Mateo I., Infante J., Llorca J., Berciano J., and Combarros O. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE4 allele. J. Neurol. 253 (2006) 181-185
32. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 70 (2002) 425-434
33. Schatz I.J., Masaki K., Yano K., Chen R., Rodriguez B.L., and Curb J.D. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 358 (2001) 351-355
34. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., and Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90 (1993) 8098-8102
35. Talmud P.J., Edwards K.L., Turner C.M., Newman B., Palmen J.M., Humphries S.E., and Austin M.A. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size. Circulation 101 (2000) 2461-2466
36. Tall A.R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34 (1993) 1255-1274
37. Teunissen C.E., Lütjohann D., von Bergmann K., Verhey F., Vreeling F., Wauters A., Bosmans E., Bosma H., van Boxtel M.P., Maes M., Delanghe J., Blom H.J., Veerbeek M.M., Rieckmann P., de Bruijn C., Steinbusch H.W., and de Vente J. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol. Aging 24 (2003) 893-902
38. Thompson J.F., Lira M.E., Durham L.K., Clark R.W., Bamberger M.J., and Milos P.M. Polymorphisms in the CETP gene and association with CETP mass and HDL levels. Atherosclerosis 167 (2003) 195-204
39. von Trotha K.T., Heun R., Schmitz S., Lütjohann D., Maier W., and Kölsch H. Influence of lysosomal acid lipase polymorphisms on chromosome 10 on the risk of Alzheimer's disease and cholesterol metabolism. Neurosci. Lett. 402 (2006) 262-266
40. Wolozin B., Kellman W., Rousseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
41. Zhu H., Gopalraj R.K., Kelly J.F., Bennett D.A., and Estus S. Lack of genetic association of cholesteryl ester transfer protein polymorphisms with late onset Alzheimer's disease. Neurosci. Lett. 381 (2005) 36-41